← Holders
EcoR1 Capital, LLC
What EcoR1 Capital, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1587114 · Filed Nov 16, 2026
- Positions
- 36
- Reported value
- $2.3B
- Opened
- 13
- Closed
- 10
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$2.1B30 positions
- Dec 31, 2025$2.2B30 positions
- Mar 31, 2026$2.4B30 positions
- Jun 30, 2026$2.1B33 positions
- Sep 30, 2026$2.3B36 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
ZYMEZymeworks Inc. | 23M | ±0% | $608.5M | 27% |
ANABAnaptysbio, Inc | 7.9M | ±0% | $396.1M | 17.6% |
| 3.5M | New | $218.4M | 9.7% | |
CGONCG Oncology, Inc. | 1.9M | +25.3% | $132.7M | 5.9% |
ETONEton Pharmaceuticals, Inc. | 2.5M | +13.8% | $127.2M | 5.6% |
TRAXFirst Tracks Biotherapeutics, Inc. | 3.2M | New | $112.5M | 5% |
AKTSAktis Oncology, Inc. | 4.8M | ±0% | $93.9M | 4.2% |
CRSPCRISPR Therapeutics AG | 1.4M | ±0% | $76.9M | 3.4% |
ANROAlto Neuroscience, Inc. | 2.2M | New | $57M | 2.5% |
LKFTLakefront Biotherapeutics NV | 1.7M | ±0% | $49.4M | 2.2% |
ERASErasca, Inc. | 3M | +793.9% | $43.2M | 1.9% |
ORICOric Pharmaceuticals, Inc. | 3M | −55.0% | $40.8M | 1.8% |
NGNENeurogene Inc. | 1.3M | ±0% | $35.4M | 1.6% |
ATTOAttovia Therapeutics, Inc. | 2M | New | $34.7M | 1.5% |
FULCFulcrum Therapeutics, Inc. | 6.8M | +3.9% | $25.2M | 1.1% |
ADRXADARx Pharmaceuticals, Inc. | 1.2M | New | $22.9M | 1% |
STOKStoke Therapeutics, Inc. | 835K | +13.6% | $21.7M | 1% |
ZBIOZenas BioPharma, Inc. | 789.5K | ±0% | $21.3M | 0.9% |
ETRAElectra Therapeutics, Inc. | 1.7M | New | $19.1M | 0.8% |
ATRAAtara Biotherapeutics, Inc. | 1.6M | ±0% | $13.2M | 0.6% |
CAPRCapricor Therapeutics, Inc. | 1.4M | New | $13M | 0.6% |
XNCRXencor Inc | 500K | New | $12.5M | 0.6% |
ODTXOdyssey Therapeutics, Inc. | 555.6K | New | $12.3M | 0.5% |
AURAAura Biosciences, Inc. | 1.7M | ±0% | $10.5M | 0.5% |
NRIXNurix Therapeutics, Inc. | 375K | +38.9% | $8.9M | 0.4% |
BRVEBraveheart Bio, Inc. | 416.7K | New | $8.4M | 0.4% |
PHVSPharvaris N.V. | 235K | ±0% | $7.5M | 0.3% |
EIKNEikon Therapeutics, Inc. | 855.6K | +16.8% | $6.9M | 0.3% |
ELOXEloxx Pharmaceuticals, Inc. | 400K | New | $6.1M | 0.3% |
AARDAardvark Therapeutics, Inc. | 720K | +81.7% | $3.8M | 0.2% |
BBOTBridgeBio Oncology Therapeutics, Inc. | 889.6K | −68.5% | $3.6M | 0.2% |
TCGXTCGX Acquisition Corp. | 250K | New | $3.1M | 0.1% |
ZURAZura Bio Ltd | 679.7K | −42.4% | $2.8M | 0.1% |
HLXCHelix Acquisition Corp. III | 200K | ±0% | $2.1M | 0.1% |
CTNMContineum Therapeutics, Inc. | 64.3K | New | $862.9K | 0.1% |
| 100 | −100.0% | $7.1K | 0.1% |